SCHEMBL4997699

SCHEMBL4997699

CCOC(=O)CNC(=O)c1c(O)nc(-c2ccccc2)[nH]c1=O

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.58
USP2 O75604 1/20 0.58
TSHR P16473 1/20 0.58
MAPK1 P28482 1/20 0.58
HPGD P15428 1/20 0.47
ERCC1 P07992 2/20 0.46
FEN1 P39748 2/20 0.46
ERCC4 Q92889 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
ALDH1A1 P00352 4/20 0.44
LMNA P02545 1/20 0.43
KDM4E B2RXH2 2/20 0.43
GAA P10253 1/20 0.43
PPID Q08752 1/20 0.43
PIN1 Q13526 1/20 0.42
ELANE P08246 1/20 0.42
RXFP1 Q9HBX9 1/20 0.41
RNASEH1 O60930 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4737701 0.85 ERCC1 (0.48) HSD17B10USP2TSHRMAPK1ERCC1
SCHEMBL3517904 0.75 HPGD (0.45) HSD17B10USP2TSHRMAPK1HPGD
SCHEMBL4992207 0.74 EGLN3 (0.54) HSD17B10TSHRHPGDSMN1; SMN2ALDH1A1
SCHEMBL4649688 0.74 KDM4E (0.44) HSD17B10USP2HPGDSMN1; SMN2ALDH1A1
SCHEMBL4737065 0.73 HPGD (0.46) HPGDERCC1FEN1ERCC4SMN1; SMN2
SCHEMBL7216561 0.72 ADORA3 (0.60) HSD17B10USP2TSHRMAPK1HPGD
SCHEMBL3516621 0.72 ALDH1A1 (0.41) HSD17B10USP2TSHRMAPK1HPGD
SCHEMBL10338070 0.71 ERCC1 (0.55) HSD17B10USP2TSHRMAPK1HPGD
SCHEMBL24005288 0.71 ALDH1A1 (0.55) HSD17B10USP2HPGDSMN1; SMN2ALDH1A1
SCHEMBL4995930 0.70 EGLN3 (0.65) HSD17B10HPGDALDH1A1LMNAPIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080171756-A1 N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2008-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080171756-A1 N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors HIF1AN, EGLN2, EGLN3 HSD17B10 429/4885USP2 2427/4885TSHR 3458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.